Cyclic Vitamin B12 Dosing for Blood Cell Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vitamin B12 supplementation regimens provide high daily doses that may not be suitable for all individuals, particularly those experiencing recurring vaginal discharge or breakthrough bleeding, and there is a concern about the safety and risk/benefit profile due to potential increased cancer risk.
Innovation Solution
Administering vitamin B12 compounds in significantly lower doses on a daily and/or periodic basis, using a non-continuous, cyclic regimen that aligns with the occurrence of recurring physiological events, such as menstruation, with a maximum daily dose of about 5 mcg and a total monthly dose of up to 35 mcg, to promote or maintain healthy blood cell levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high daily doses of vitamin B12 (50-10,000 mcg) are administered, then blood cell levels are replenished and health conditions are improved, but the risk of cancer and other harmful effects increases
Solution Approach 1:
The patent fundamentally changes the dosage parameter from conventional high doses (50-10,000 mcg/day) to low doses (1-12 mcg/day), and changes the administration frequency from daily continuous to periodic intermittent dosing. This parameter transformation maintains therapeutic effectiveness while reducing harmful effects, as evidenced by the specification stating that low periodic doses achieve blood cell replenishment without the cancer risk associated with high continuous doses.
Solution Approach 2:
The patent implements periodic intermittent administration of vitamin B12 instead of continuous daily dosing. The specification describes administering vitamin B12 at periodic intervals (e.g., once or twice weekly, or once monthly) rather than every day. This periodic action maintains adequate blood cell levels while minimizing cumulative exposure to potential harmful effects, resolving the contradiction between effectiveness and safety.
2Reliability
If continuous daily supplementation is provided, then vitamin B12 deficiency is prevented, but unnecessary exposure to potential harmful effects occurs during periods when deficiency risk is low
Solution Approach 1:
The patent employs periodic intermittent dosing regimens that align with the physiological cycle of vitamin B12 depletion and replenishment. The specification indicates that vitamin B12 stores are depleted over time (particularly during menstruation) and can be replenished with periodic dosing. By administering vitamin B12 at strategic intervals rather than continuously, the patent prevents deficiency when risk is high while minimizing unnecessary exposure when risk is low, thus resolving the contradiction between reliable prevention and harmful exposure.
Solution Approach 2:
The patent leverages the body's natural ability to store and regulate vitamin B12, allowing it to maintain adequate levels between dosing intervals. The specification notes that the body can maintain vitamin B12 status with periodic supplementation by utilizing its own regulatory mechanisms and storage capacity. This self-service approach reduces the need for continuous dosing while maintaining reliability in preventing deficiency.
Data Source
AI summary
The invention described herein provides new methods and compositions for the cyclical provision of a vitamin B12 compound in a dosing regimen wherein the total amount of vitamin B12 administered during any one treatment cycle does not exceed 35 mcg. More specifically, the invention described in this disclosure promotes the prevention or treatment of a vitamin B12 deficiency, supports the replenishment and or maintenance of healthy blood cell levels, or both, particularly in those experiencing a periodic physiological challenge which may compromise vitamin B12 status or result in an increased requirement for vitamin B12, such as the monthly blood loss experienced by a reproductively cycling human female.